SAN FRANCISCO, CA—A head-to-head comparison of two coronary stents with biodegradable polymers in an all-comers population showed that the Orsiro ultrathin strut drug-eluting stent (Biotronik) was ...
PARIS — In the ongoing saga of stent vs stent, the latest chapter shows that at 1 year of follow-up, a thin-strut, everolimus-eluting stent with a bioabsorbable-polymer (Synergy, Boston Scientific) ...
SAN FRANCISCO, CA - Patients who develop stent thrombosis after percutaneous coronary intervention are more likely to have uncovered and/or malapposed stent struts, according to data presented ...
PARIS, France — A new sirolimus-eluting stent boasting a biodegradable polymer and a thin-strut design that is 25% thinner than the market-leading, permanent-polymer stent has shown promising results ...
A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In the overall cohort of a randomized trial, three ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “The final 5-year follow-up data confirms Orsiro’s ...
BUELACH, SWITZERLAND--(Marketwired - May 30, 2013) - Primary end-point results from the BIOFLOW-II Clinical Study demonstrating the non-inferiority of the BIOTRONIK Orsiro Hybrid Drug-Eluting Stent ...
Treating chronic total occlusions can be challenging. Results from a multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a ...
Do you know immunotherapy post-surgery improves overall survival for kidney cancer? Study finds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback